Compare MUJ & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MUJ | PRTA |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 631.8M | 595.9M |
| IPO Year | N/A | N/A |
| Metric | MUJ | PRTA |
|---|---|---|
| Price | $12.13 | $9.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.86 |
| AVG Volume (30 Days) | 108.0K | ★ 617.1K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,786,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $819.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.74 | $4.32 |
| 52 Week High | $11.70 | $17.66 |
| Indicator | MUJ | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 64.83 | 36.68 |
| Support Level | $11.96 | $9.69 |
| Resistance Level | $12.09 | $10.50 |
| Average True Range (ATR) | 0.10 | 0.57 |
| MACD | -0.00 | -0.16 |
| Stochastic Oscillator | 82.86 | 6.50 |
BlackRock MuniHoldings New Jersey Quality Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund mainly invests in long-term, investment-grade municipal obligations exempt from U.S federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax) and New Jersey personal income taxes, with remaining maturities of one year or more at the time of investment. The rest of its managed assets can be invested in securities that are rated below investment grade (or similar instruments), or invested directly in securities or synthetically through the use of derivatives.
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.